Donate For Public and Patients Store Search

S061 - Cutting Edge Multidisciplinary Care of the CTCL Patient

Monday, March 4; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe the many advantages of single site multidisciplinary care for the CTCL patient as opposed to fragmented multi-site care
  • Outline the different treatment approaches to patients with different types of CTCL, based upon scientific advances, new therapies, and advanced tools
  • Describe how understanding the basic biology of CTCL and T lymphocytes can guide decisions about therapeutic strategies

Description

Cutaneous T cell lymphomas range from minor diseases with indolent life-long courses to aggressive life-threatening lymphomas potentially curable only by hematopoietic stem cell transplantation (HSCT). Our approach to the management non-indolent CTCL involves the collaborative efforts of physician-experts and physician-scientists in CTCL. These include Dermatologic-Oncologists, Radiation-Oncologists, Medical-Oncologists, HSCT-Oncologists, Nurse Practitioners, PA's, and research nurses dedicated to cutaneous lymphomas, all practicing in the same setting. Translational research studies provide bedside-to-bench, and bench-to-bedside insights that continue to improve patient care. A robust clinical trials program expands therapeutic options for our patients. Multidisciplinary care is superior.

Disclosures

  • Clark, Rachael, MD, PhD: Sanofi – A(H);
  • Cutler, Corey, MD: no financial relationships exist with commercial interests.
  • Devlin, Phillip, MD: Demos Medical Publishing – O(IP);
  • Fisher, David C., MD: Celgene Corporation – A(Fees); Gilead Sciences, Inc. – A(Fees);
  • Kupper, Thomas, MD: Adaptive Biotechnologies Corporation – A(NC); TremRX – B(NC);
  • Larocca, Cecilia, MD: no financial relationships exist with commercial interests.
  • LeBoeuf, Nicole, MD: Bayer – Speaker/Faculty Education(H);
  • Mitchum, Marsha D, MD, MPH: no financial relationships exist with commercial interests.
  • O'Malley, John, MD, PhD: no financial relationships exist with commercial interests.
Schedule
Monday, March 4
1:00 PM
Dr. Kupper / Introduction
1:05 PM
Dr. LeBoeuf / CTCL Subtypes
1:25 PM
Dr. Clark / The Biology of MF and Leukemic CTCL
1:45 PM
Dr. O'Malley / High Throughput Sequencing of TCR genes
2:05 PM
Dr. Devlin / Radiation Oncology and CTCL
2:25 PM
Dr. Larocca / Dermatologic Oncology and Skin Directed Therapy
2:45 PM
Fisher / Medical Oncology and CTCL
3:05 PM
Cutler / Hematopoietic Stem Cell Transplantation: Why and When
3:20 PM
All faculty / Multidisciplinary Cases
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 101
  • CME Credits
    3.00
  • Type
    New
Directors/Co-Directors
  • Thomas Kupper, MD, FAAD
Speakers
  • Cecilia Larocca, MD, FAAD
  • Corey Cutler, MD
  • David C. Fisher, MD
  • John O'Malley, MD, PhD, FAAD
  • Marsha D Mitchum, MD, MPH
  • Nicole LeBoeuf, MD, FAAD
  • Phillip Devlin, MD
  • Rachael Clark, MD, PhD, FAAD